ICN Pharmaceuticals licenses two NSAIDS from Roche subsidiary

ICN to distribute Naprosyn and Apranaxin in Hungary, the Czech Republic, Slovakia, Poland, and the Russian Federation

ICN Pharmaceuticals Inc. (Costa Mesa, CA) has acquired the rights to two non-steroidal anti-inflammatory drugs from an affiliate of F. Hoffman-La Roche Ltd. for certain Eastern European markets, ICN announced this week.

ICN had been manufacturing Naprosyn (naproxen acid) and Apranax (naproxen sodium) and distributing the products under license from Roche in Hungary, the Czech Republic, and Slovakia. The new agreement transfers all rights for Naprosyn and Apranax from Roche and its affiliates to ICN in these markets, as well as in Poland and the Russian Federation. Terms and conditions of the deal were not disclosed.

Naprosyn and Apranax are oral non-steroidal analgesics and anti-inflammatory agents used to relieve mild to moderate pain from many conditions, including arthritis.

ICN manufactures, markets, and distributes prescription and non-prescription pharmaceuticals, including anti-infectives, anti-virals, and anti-cancer drugs.

For more information: ICN Pharmaceuticals Inc., 3300 Hyland Ave., Costa Mesa, CA 92626. Tel: 714-545-0100 or 800-548-5100. Fax: 714-556-0131.

With contributions from Jim Pomager
Assistant Editor, Pharmaceutical Online
Source: ICN Pharmaceuticals Inc.